Prasterone
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Prasterone |
| DrugBank ID | DB01708 |
| Brand Names (EU) | Intrarosa |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
Intrarosa is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | heparin cofactor 2 deficiency | 99.99% | DL |
| 2 | factor 5 excess with spontaneous thrombosis | 99.98% | DL |
| 3 | antithrombin deficiency type 2 | 99.98% | DL |
| 4 | thrombophilia | 99.91% | DL |
| 5 | pediatric systemic lupus erythematosus | 99.25% | DL |
| 6 | severe nonproliferative diabetic retinopathy | 99.25% | DL |
| 7 | thrombophilia due to protein S deficiency, autosomal recessive | 99.13% | DL |
| 8 | scleroderma (disease) | 99.11% | DL |
| 9 | complement component 4a deficiency | 99.05% | DL |
| 10 | pseudo-von Willebrand disease | 99.01% | DL |
| 11 | primary release disorder of platelets | 99.01% | DL |
| 12 | acne (disease) | 98.54% | DL |
| 13 | anus disease | 97.79% | DL |
| 14 | granulomatous disease, chronic, autosomal recessive, 5 | 97.37% | DL |
| 15 | inflammatory bowel disease | 97.26% | DL |
| 16 | granulomatous disease with defect in neutrophil chemotaxis | 97.20% | DL |
| 17 | fetal and neonatal alloimmune thrombocytopenia | 97.05% | DL |
| 18 | peeling skin syndrome | 97.00% | DL |
| 19 | spondyloarthropathy, susceptibility to | 96.97% | DL |
| 20 | diabetic retinopathy | 96.90% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.